AOD9604
Also known as: Anti‑Obesity Drug 9604, AOD-9604, AOD‑9604, GH fragment 177‑191, HGH Frag 176-191, hGH Fragment 176-191, Tyr-hGH177-191
Source AOD9604 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
A synthetic 15‑amino‑acid fragment of human growth hormone developed as an anti‑obesity agent. Demonstrated modest fat‑loss effects in early trials but has not received regulatory approval.
Mechanism of Action
C‑terminal fragment of human growth hormone (residues 177‑191) that stimulates lipolysis and inhibits lipogenesis, purportedly via GH‑receptor‑independent pathways affecting adipocyte metabolism.
Routes of Administration
Goals & Uses
- Fat loss / lipolysisBody CompositionModerate
- Improved body compositionMetabolicLow
- Weight lossMetabolicModerateChronic weight management and appetite reduction
- Anti-lipogenic effectMetabolicModerate
- Cartilage and bone repairRegenerativeLow
- Metabolic syndrome improvementMetabolicLow
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- known hypersensitivity to peptideImmunologicModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to hGH fragmentsImmunologicalHigh
Adverse Effects
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- FlushingVascularUncommonWarmth and redness of the skin
- Transient hyperglycemiaMetabolic/EndocrineRare
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- Insulin / antidiabetic agentsLow
- Full-length recombinant human growth hormone (rhGH)Low
- Other GH analoguesModerate
Population Constraints
- Elderly (>65 years)AgeRelative
- Children (<18 y)AgeRelative
- Pediatric populationAgeAbsolute
- Lactating womenReproductiveAbsolute
Regulatory Status
- European UnionInvestigationalClinical trials conducted; no marketing authorization.
- United StatesInvestigationalInvestigational New Drug (IND) status; not FDA‑approved.
- United KingdomInvestigationalUsed only in research settings.
Not approved by FDA, EMA or MHRA. Clinical development halted in several jurisdictions; currently marketed only as a research chemical.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is AOD9604?
A synthetic 15‑amino‑acid fragment of human growth hormone developed as an anti‑obesity agent. Demonstrated modest fat‑loss effects in early trials but has not received regulatory approval.
What is AOD9604 used for?
AOD9604 is educationally associated with: Fat loss / lipolysis, Improved body composition, Weight loss, Anti-lipogenic effect, Cartilage and bone repair, Metabolic syndrome improvement. Educational only — not medical advice.
How is AOD9604 administered?
Recorded routes of administration: Nasal, Oral, Subcutaneous.
What are the potential side effects of AOD9604?
Reported adverse effects include: Injection site reactions, Headache, Flushing, Transient hyperglycemia, Nausea, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid AOD9604?
Recorded contraindications: Active malignancy, known hypersensitivity to peptide, Pregnancy, Hypersensitivity to hGH fragments. Consult a qualified clinician before use.